Synovial sarcoma is a rare, aggressive cancer that develops in soft tissues, most often near large joints like the knee, ankle, or shoulder. It accounts for 5% to 10% of all soft tissue sarcomas and primarily affects younger adults, with a median age at diagnosis of about 30 years. Despite its name, it does not originate from the synovial lining of joints. The name is a historical holdover from early pathologists who thought the tumor cells resembled synovial tissue under the microscope.
Who Gets Synovial Sarcoma
This cancer has an unusual demographic profile compared to most cancers: it disproportionately strikes young people. The peak incidence falls in the third to fourth decade of life, and roughly one third of patients are diagnosed before age 30. It can occur at any age, but it is rare in children under 10 and in older adults. There is no well-established environmental or lifestyle risk factor. The defining genetic event appears to happen spontaneously rather than being inherited.
The Genetic Driver Behind It
Nearly every synovial sarcoma carries the same genetic abnormality: a swap of material between chromosome X and chromosome 18. This translocation fuses two genes together, creating an abnormal protein that disrupts how cells regulate their genes. In most cases, the fusion involves one of two closely related partner genes, with about 43% of tumors carrying one variant and 31% carrying the other. This fusion protein is considered the primary driver of the disease, essentially reprogramming normal cell behavior to promote tumor growth. Because this translocation is present in virtually all cases, detecting it through molecular testing is one of the most reliable ways to confirm a diagnosis.
Symptoms and Common Locations
Synovial sarcoma most commonly appears in the arms and legs, particularly around the knee and thigh. It can also develop in the trunk, head and neck region, or, less frequently, in the lungs or abdomen. The tumor typically presents as a slow-growing, deep-seated mass near a joint or tendon. Many patients notice a painless lump that has been present for weeks or months before they seek medical attention. Pain develops in some cases, especially as the tumor grows large enough to press on nearby nerves or structures.
Because it tends to grow slowly at first and often affects young, otherwise healthy people, synovial sarcoma is frequently mistaken for a benign cyst, a sports injury, or a swollen lymph node. This can lead to significant delays in diagnosis. Any soft tissue mass that persists for more than a few weeks, is larger than a golf ball, or is growing steadily warrants medical evaluation.
How It Is Diagnosed
Diagnosis begins with imaging, usually an MRI of the affected area, which helps define the tumor’s size, depth, and relationship to surrounding structures. A biopsy is then performed, most often a core needle biopsy, to obtain tissue for examination under a microscope.
Under the microscope, synovial sarcoma comes in three forms. The monophasic type, which is the most common, consists entirely of uniform spindle-shaped cells. The biphasic type contains both spindle cells and cells that form gland-like structures. A third, poorly differentiated type features more chaotic-looking cells with higher rates of cell division. These subtypes matter because poorly differentiated tumors tend to behave more aggressively.
Pathologists use a combination of protein markers on the tumor cells and molecular tests to confirm the diagnosis. The tumor cells typically show certain protein signatures that help distinguish them from other soft tissue cancers. The definitive confirmation comes from detecting the characteristic chromosomal translocation, which can be identified through specialized laboratory techniques. This molecular fingerprint is so specific to synovial sarcoma that it essentially rules out other diagnoses when present.
Treatment Approach
Surgery to remove the tumor with clear margins is the cornerstone of treatment. The goal is to excise the entire tumor along with a surrounding cuff of healthy tissue. In most cases, limb-sparing surgery is possible, and amputation is rarely necessary thanks to advances in surgical techniques and the use of radiation therapy.
Radiation therapy is commonly used either before or after surgery. Preoperative radiation can shrink the tumor and make it easier to remove, while postoperative radiation targets any microscopic disease left behind. The choice of timing depends on the tumor’s size, location, and other clinical factors.
Chemotherapy plays a more nuanced role. For high-risk tumors (those that are large, deep, or high-grade), chemotherapy before or after surgery can improve outcomes. One large study found that patients with high-risk soft tissue sarcomas who received chemotherapy had a median disease-free survival of 48 months compared to 16 months with surgery alone, and overall survival improved from 46 months to 75 months. However, the benefits must be weighed against the side effects, and the role of chemotherapy remains a topic of ongoing clinical discussion. When chemotherapy is used for advanced or metastatic disease, anthracycline-based regimens are the standard first-line option.
A New Type of Treatment
In August 2024, the FDA granted accelerated approval to a new engineered T-cell therapy (sold as Tecelra) specifically for adults with synovial sarcoma that cannot be surgically removed or has spread, and who have already tried chemotherapy. This therapy works by collecting a patient’s own immune cells, genetically modifying them in a lab to recognize a specific protein found on synovial sarcoma cells, and infusing them back into the patient.
In the clinical trial that led to approval, 44 patients received the treatment. The overall response rate was 43%, meaning the tumors shrank meaningfully in nearly half of patients. The median time to see a response was about five weeks, and among those who responded, 39% maintained their response for 12 months or longer. This therapy is only available to patients whose tumors express a specific target protein and who carry certain immune system markers, so not everyone with synovial sarcoma is eligible. Still, it represents the first cell-based therapy approved for a solid tumor cancer.
Survival and Prognosis
Prognosis depends heavily on how far the cancer has spread at diagnosis. For soft tissue sarcomas overall (which includes synovial sarcoma), the five-year relative survival rate is 83% when the cancer is still confined to its original site, 60% when it has spread to nearby lymph nodes, and about 17% when it has metastasized to distant organs. The majority of patients, roughly 57%, are diagnosed at the localized stage.
Tumor size, depth, and histologic grade also influence outcomes. Tumors smaller than 5 centimeters that are superficial and low-grade carry the best prognosis. Poorly differentiated tumors, larger tumors, and those in deep locations carry higher risk of recurrence and metastasis.
Monitoring After Treatment
The lungs are the most common site of metastasis for synovial sarcoma, and spread to the lungs most often occurs within the first two to three years after diagnosis. Because of this, patients undergo regular imaging surveillance after completing treatment. Current guidelines from the National Comprehensive Cancer Network recommend CT scans for lung monitoring, though chest X-rays can be used for longer-term follow-up to reduce cumulative radiation exposure. Scans are typically scheduled every three to six months during the highest-risk period, then gradually spaced out over time. Local recurrence at the original tumor site is also possible and is monitored with periodic MRI.